Items where authors include "Crabb, S."

Article

Griffin, J. orcid.org/0000-0003-3969-7637, Down, J., Quayle, L.A. et al. (10 more authors) (2024) Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. The Journal of Pathology: Clinical Research, 10 (2). e12363. ISSN 2056-4538

Critchlow, S. orcid.org/0000-0001-6862-765X, Bullement, A. orcid.org/0000-0001-7091-0972, Crabb, S. orcid.org/0000-0003-3521-9064 et al. (9 more authors) (2023) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology. ISSN 1479-6694

Fulton, B., Jones, R., Powles, T. et al. (8 more authors) (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21. 344. ISSN 1745-6215

Crabb, S., Danson, S.J., Catto, J.W.F. orcid.org/0000-0003-2787-8828 et al. (12 more authors) (2018) SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. Trials, 19. 216. ISSN 1745-6215

Powles, T., Brown, J., Larkin, J. et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534

Proceedings Paper

Critchlow, S., Xiao, Y., Crabb, S. et al. (9 more authors) (2022) POSC4 Modeling health-related outcomes with avelumab as a first-line maintenance treatment following chemotherapy vs. best supportive care (BSC) for patients with locally advanced or metastatic urothelial cancer in the UK. In: Value in Health. Virtual ISPOR Europe 2021, 30 Nov - 03 Dec 2021, Virtual conference. Elsevier BV , S32-S33.